Available COVID-19 vaccines are most often administered intramuscularly and primarily elicit IgG antibody response, with a weak response of mucosal IgA antibodies, which have a superior antiviral effect at the entry points of infection [34–36]. This evidence concerns the gene CD79A and infection.